ClinicalTrials.gg
RecruitingNCT06845319NeoCARDUpdated May 6, 2026

NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

A Phase 2 interventional study of Carboplatin and Paclitaxel in Triple Negative Breast Cancer, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Medical University of South Carolina · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies testing carboplatin in Triple Negative Breast Neoplasms — 16 open to participants now, 29 under way, 5 of them phase 3. Carboplatin · Triple Negative Breast Neoplasms.

Planned enrollment
32nd of 56
43 · median 52
Started
2025
with 3 others
Phase 2
43 of 56
16 open now
Primary completion
2027-10
later than 21 of 28 live
Registered
51st of 56
by date
Lead sponsor
2 of 56
Medical University of South Carolina

Among the 56 studies testing carboplatin in Triple Negative Breast Neoplasms, this one is the 32nd largest by planned enrollment, is one of 4 that started in 2025, is one of 43 in phase 2, reaches primary completion later than 21 of the 28 other live ones, and was the 51st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

16 of the 56 studies testing carboplatin in Triple Negative Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing carboplatin in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardiac conditions.

Read the detailed description

Clinical trial participation among patients with cardiac co-morbidities is limited, creating challenges for oncologists managing aggressive cancers like Triple Negative Breast Cancer (TNBC) in this demographic. At MUSC and its affiliated rural sites, a significant portion of our patient population presents with complex medical histories and co-morbidities that increase their risk for anthracycline-induced cardiotoxicity. Therefore, proposing a dedicated study focused on patients with pre-existing cardiomyopathy or those at high risk for cardiotoxicity-using a non-anthracycline-based regimen-is both timely and essential.

Rationale for Using Paclitaxel, and Carboplatin with Immunotherapy:

It is estimated that around 60% of TNBC patients exhibit a "BRCAness" phenotype, which mirrors the clinical characteristics of tumors with BRCA mutations. Consequently, the use of DNA-damaging agents, like platinum-based therapies, has gained prominence as a viable treatment option for these patients. Several studies have demonstrated that adding carboplatin to neoadjuvant chemotherapy regimens improves the pCR rates in TNBC patients. While some trials have also shown improvements in disease-free survival, others have not observed this benefit. Notably, a recent study from India highlighted an overall survival advantage, specifically in TNBC patients under the age of 50, when carboplatin was included in their treatment.

Platinums have also been shown to modulate the immune system and cause immunogenic mediated cell death whereby they can increase major histocompatibility complex (MHC) class I expression on cancer cells thus promoting T-cell activation. Although platinums on their own could induce an immune response, a combination with taxanes like paclitaxel has been shown to augment this response as evidenced by decreasing T regulatory cells and increasing the proportions of T-helper cells and natural killer cells. In a mouse study looking at combining cisplatin with paclitaxel and immunotherapy, it was found that chemotherapy enhanced immune-mediated cancer cell death by decreasing intratumoral T regulatory cells and increasing the recruitment of cytokine-induced killer cells.

Beyond its direct cytotoxic activity as a microtubule-stabilizing agent, paclitaxel exerts potent immunomodulatory effects that make it an attractive chemotherapeutic backbone for combination with immune checkpoint inhibitors in triple-negative breast cancer (TNBC). Three key preclinical mechanisms support this rationale. First, paclitaxel functions as a Toll-like receptor 4 (TLR4) agonist by directly binding the MD-2 accessory molecule of the TLR4 complex on myeloid cells, mimicking bacterial lipopolysaccharide and activating TLR4/TRIF/IRF3 signaling to induce type I interferons and CTL-attracting chemokines within the tumor microenvironment; this TLR4 activation reprograms tumor-associated macrophages from an immunosuppressive M2 phenotype to a pro-inflammatory M1 phenotype, enhances antigen cross-presentation, and is associated with upregulated IFNα/IFNγ signaling in paclitaxel responders. Second, paclitaxel enhances dendritic cell maturation and antigen-presenting function through TLR4 signaling, increasing expression of co-stimulatory molecules (CD80, CD86, CD40), MHC class II, and IL-12, and generating CD8⁺ T cells with markedly increased lytic activity against tumor cells; in vivo, paclitaxel treatment expands antigen-specific, IFNγ-secreting CD8⁺ T cells in vaccine-draining lymph nodes, an effect abrogated by TLR4 blockade. Third, paclitaxel induces immunogenic cell death, with treated tumor cells exposing calreticulin and releasing HMGB1 and other DAMPs that promote phagocytic uptake and TLR4-dependent innate immune activation, while cytoplasmic DNA from dying cells triggers cGAS/STING/IRF3 signaling and further type I interferon and chemokine production, functionally mimicking an in situ vaccination. Collectively, TLR4-mediated macrophage reprogramming, enhanced dendritic cell maturation, and immunogenic cell death converge to convert the tumor microenvironment from immunologically "cold" to "hot," creating optimal conditions for PD-1/PD-L1 blockade. In TIL-high TNBC, where a pre-existing adaptive immune response is present, paclitaxel amplifies this endogenous immunity, providing a strong mechanistic rationale for its use as the chemotherapeutic backbone in a de-escalated chemoimmunotherapy regimen.

Rationale for Weekly Paclitaxel Over Taxotere:

In the ECOG E1199 trial, 4,954 patients with stage II-III breast cancer received AC×4 followed by randomization to paclitaxel or docetaxel given either every 3 weeks or weekly, in a 2×2 factorial design with DFS as the primary endpoint. After 12.1 years of follow-up, both weekly paclitaxel and every-3-week docetaxel produced significantly superior DFS and numerically better OS compared with every-3-week paclitaxel, whereas the other experimental arm (weekly docetaxel) did not. In the triple-negative subset (n≈1,025), weekly paclitaxel emerged as the most effective regimen, yielding a \~30% relative reduction in recurrence and death (HR 0.69 for both DFS and OS) and the highest 10-year DFS (69%) and OS (75%) among the four taxane schedules.

In terms of chemotherapy-related toxicities, every 3-week docetaxel was associated with higher levels of grade 4 toxicities than weekly paclitaxel 50% versus 4% respectively and most of the side effects are related to grade 4 neutropenia (46% vs 2%), febrile neutropenia (16% vs 1%), grade 3-4 stomatitis, fatigue, and myalgias. Conversely, the paclitaxel group had a higher level of grade 3 or 4 neuropathy of around 8% versus 4%. Unique to docetaxel, patients can also experience fluid retention syndrome often requiring prophylaxis with corticosteroids. This can manifest as peripheral edema, pleural effusions, ascites, or generalized weight gain. The condition is dose-dependent and typically more pronounced in patients receiving higher cumulative doses of docetaxel. In patients with underlying cardiomyopathy, this adverse effect can pose significant clinical challenges. Therefore, docetaxel is avoided in the NeoCARD study to reduce the risk of neutropenia, fluid overload and cardiac decompensation in this vulnerable population.

Rationale for a 12-Week Regimen:

The effectiveness of regimens featuring weekly taxanes with carboplatin is highlighted in studies like the WSG-ADAPT TN study and the NeoN phase 2 study by Loi et al. A 12-week platinum/taxane/pembrolizumab protocol may achieve pCR in chemo-sensitive patients without the need for prolonged chemotherapy. However, individuals with poor response rates may require extended therapy. Early identification of responders through radiographic methods could enable de-escalation strategies, potentially reducing long-term toxicities such as neuropathy that significantly impact quality of life.

Rationale for Response Adaptive Study Design:

MRI stands out as the most accurate imaging modality for assessing pCR in TNBC patients, with reported accuracy rates exceeding 86%. Therefore, MRI is endorsed as the optimal tool for assessing response by the American College of Radiology (ACR) and the Society of Breast Imaging (SBI).

A prospective, multi-institutional trial (ACRIN 6657/I-SPY TRIAL) demonstrated that MRI-based functional tumor volume measurements after neoadjuvant chemotherapy not only predict pathologic response but also correlate with recurrence-free survival. Specifically, functional tumor volume measured by MRI was shown to predict recurrence-free survival in patients with stage II or III breast cancer undergoing neoadjuvant therapy.

Overall, MRI response adaptive neoadjuvant therapy in breast cancer provides early detection of changes in tumor size and morphology, facilitating prompt assessment of treatment response. Additionally, MRI findings, including alterations in tumor enhancement patterns, can predict pathologic response to therapy, informing decisions about achieving a complete response. These MRI results also guide tailored treatment planning, determining the necessity of additional therapy and suitability for breast-conserving surgery versus mastectomy.

03

Conditions studied

  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, an individual must meet all of the following criteria:

  1. confirmed triple-negative breast cancer (TNBC) or hormone receptor-low invasive breast carcinoma, with clinical anatomic Stage II or Stage IIIA/B disease as defined by the AJCC 8th Edition Breast Cancer Stating System.

    a) The invasive tumor must be hormone receptor-negative or low, defined as estrogen receptor (ER) and/or progesterone receptor (PR) staining present in ≤10% of invasive cancer cells by immunohistochemistry (IHC).

    b) -negative disease, defined in accordance with current ASCO-CAP HER2 guidelines.

  2. Measurable or evaluable tumor in the breast larger than 1 cm, with or without axillary involvement.
  3. Patients with multifocal or multicentric disease are eligible, provided the dominant tumor focus is ER and/or PR ≤10% and HER2 negative.
  4. Female or male, age ≥18 years.
  5. (ECOG) performance status of 0 to 2.
  6. Medically fit to undergo curative-intent breast surgery per institutional standard of care.
  7. No prior chemotherapy, immunotherapy, radiation therapy, or surgery for the current breast cancer (diagnostic core or vacuum-assisted allowed).
  8. Ability to be followed by a cardiologist and/or primary care physician for optimization of cardiac comorbidities, as needed.
  9. Adequate organ function at the time of screening, defined as:

    a) Hematologic

    1. ≥1,500/µL.
    2. count ≥100,000/µL.
    3. Leukocytes ≥3,000/µL.
    4. ≥9.0 g/dL or ≥5.6 mmol/L (without erythropoietin dependency and without packed red blood cell transfusion within 14 days prior to testing).

    b) Renal

    a. Serum creatinine ≤1.5 mg/dL or ≥50 mL/min. Note: Patients with creatinine clearance 30-50 mL/min may be enrolled at the discretion of the Principal Investigator, given that paclitaxel is primarily hepatically metabolized and carboplatin dosing can be adjusted to renal function.

    c) Hepatic

    1. (SGOT) and ALT (SGPT) ≤2.5 × .
    2. Serum albumin ≥3.0 g/dL.
    3. Participants without a history of Gilbert's syndrome must meet one of the following:

    i. Total ≤1.5 × IULN, or ii. Total bilirubin >1.5 × IULN with direct bilirubin ≤ULN. d. Participants with a history of Gilbert's syndrome must have total bilirubin ≤5 × ULN.

    d) Coagulation

    a. For patients receiving anticoagulant therapy, PT and/or within the therapeutic range for the intended use of anticoagulants.

    b. For patients not receiving anticoagulant therapy, INR, PT, and aPTT ≤1.5 × ULN.

  10. Breast and axillary imaging (including ultrasound and MRI) within 42 days (6 weeks) prior to registration.
  11. Patients with clinically and/or radiologically abnormal axillary lymph nodes must have pathological confirmation with image-guided core biopsy or fine needle aspiration showing carcinoma.
  12. Patients should undergo staging scans to exclude metastatic disease if any of the following apply:

    a) Axillary imaging shows two or more abnormal lymph nodes, or b) There are clinical signs or symptoms concerning for metastatic disease, or c) At the treating physician's discretion.

  13. Patients with bilateral breast cancer are eligible if both tumors are HER2 negative and all other eligibility criteria are met (eligibility should be determined based on the higher-risk side when applicable).
  14. Baseline peripheral neuropathy grade ≤2 (per ).
  15. An individual of must be willing and able to use highly effective from the time of , throughout study treatment, and for at least 6 months after the last dose of trial therapy.

    Note: Highly effective contraception is defined as methods with a failure rate \<1% per year when used consistently and correctly, and include: copper intrauterine device (IUD); bilateral tubal ligation/occlusion or other documented surgical sterilization; vasectomized partner with documented azoospermia, provided this is the sole sexual partner; or true sexual abstinence, defined as complete abstinence from heterosexual intercourse, when this is the participant's usual and preferred lifestyle. Use of hormonal contraceptive methods (including combined oral contraceptives, progestin-only pills, injectables, implants, hormonal IUDs, patches, or vaginal rings) is not permitted during the study.

  16. Ability and willingness to comply with all study procedures, including scheduled visits, treatment plans, laboratory tests, and other study requirements.
  17. Ability and willingness to sign and date written informed consent prior to initiation of any study-specific procedures.
  18. Participants with known (HIV) infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration.
  19. Participants with evidence of chronic virus (HBV) infection must have undetectable HBV load while on suppressive therapy on the most recent test results obtained within 6 months prior to registration, if indicated. NOTE: No testing for Hepatitis B is required unless mandated by local health authority.
  20. Participants with a history of virus (HCV) must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to randomization, if indicated. NOTE: No testing for Hepatitis C is required unless mandated by local health authority.
  21. Patient is ineligible for anthracycline treatment due to at least one of the following of A, B, C, or D:

    1. Individuals identified as being at high risk for cardiotoxicity from anthracycline treatment have one or more of the following characteristics.

1. Preexisting cardiomyopathy with (EF) between 25-49%. 2. Severe valvular disease on echocardiogram. 3. Previous exposure to anthracyclines. 4. Previous exposure to high dose chest wall radiation >30Gy. 5. Participants who have experienced myocardial infarction, unstable angina pectoris, an arterial thrombotic event, or stroke, within the last 12 months but not less than 3 months ago.

b) Medium or high risk for Congestive Heart Failure (CHF) at 3 years as defined by the Cardiotoxicity Prediction Tool from Ezaz et al. [24]

c) Patients declining anthracycline therapy after thorough discussion regarding its significant role in treating TNBC.

d) Patients who are deemed ineligible for anthracycline due to other medical conditions not listed here, as determined by the primary oncologist and confirmed by the study PI.

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Subject is planning to participate, currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  2. Current diagnosis of or inflammatory breast cancer.
  3. Patients deemed unfit to undergo curative surgery according to the standard of care.
  4. Patients who have concomitant and/or previous within the last 5 years.

    Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., ductal carcinoma in situ (DCIS), carcinoma in situ of the cervix) that have undergone potential curative therapy are NOT excluded.

  5. History of to compounds that are similar to carboplatin and paclitaxel.
  6. Has received major surgery and has not recovered adequately from the toxicity and/or complications before starting study treatment.
  7. Subject has received a within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza or COVID vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  8. Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy (7-day clearance period for immunosuppressant therapy prior to starting study treatment, if applicable).
  9. Has active disease that has required systemic treatment in the past 1 year (i.e., with the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
  10. Has a history of solid organ transplant.
  11. Has a history of non-infectious pneumonitis that required high-dose steroids and/or has current pneumonitis.
  12. Has an active bacterial infection requiring systemic therapy.
  13. Known psychiatric or substance abuse disorders that would interfere with the requirements of the trial.
  14. Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study, starting with the screening visit through 180 days after the last dose of trial treatment.
  15. Subject is a who has had a positive urine pregnancy test within 24 hours prior to initiation of study treatment. Females will be determined to be not of child-bearing potential with a history of hysterectomy or with status of >12 months.
  16. Uncontrolled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg), or uncontrolled or symptomatic arrhythmia at the time of screening visit.
  17. At the time of the screening visit, EF is less than 25%.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    TNBC + non inflammatory Stage 2 3A/B

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Pembrolizumab

Interventions

  • Carboplatin target AUC 5 every 3 weeks for 12-18 weeks OR target AUC 1.5 every week for 12-18 weeks (per investigator's choice).

  • 80mg/m2 weekly

  • 200 mg every 3 weeks for 4 cycles

06

What researchers measure

Primary outcomes

  1. pCR Rate in TNBC patients

    To determine the pCR rate in TNBC patients treated with the 12-18 weeks CPP regimen

    Time frame: 18 weeks

Secondary outcomes

  1. Radiological Response

    To evaluate radiologic response rate (RRR) at 12-week MRI defined by complete response and partial response.

    Time frame: 12 weeks

  2. Minimal Residual Disease Rate

    To evaluate the minimal residual disease (MRD) rate (residual cancer burden score of 0+1) with the neoadjuvant CPP regimen

    Time frame: 18 Weeks

  3. Event Free Survival

    To determine 3-year event-free survival (EFS) with a neoadjuvant CPP regimen

    Time frame: 3 years

  4. Overall Survival

    To determine 3 and 5-year overall survival (OS) with a neoadjuvant CPP regimen

    Time frame: 5 years

  5. Quality of life of patients with cardiac conditions undergoing the CPP regimen.

    Quality of life (QOL) will be evaluated using PROMIS-29 Profile v2.1 at baseline, at the conclusion of NAC and again at 12 months postNAC.

    Time frame: 5 years

  6. To evaluate the toxicity of neoadjuvant CPP regimen in TNBC patients with underlying cardiac conditions

    Toxicity will be assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 4.03. Start of study treatment (cycle 1 day 1) until 30 days after last dose of study treatment.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 24 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 25, 2025
StartActual
Oct 20, 2025
Primary completionEst.
Oct 20, 2027
CompletionEst.
Oct 20, 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06845319
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Oct 20, 2025
Primary completion
Oct 20, 2027 (estimated)
Completion
Oct 20, 2028 (estimated)
Last update
May 6, 2026

Study contacts

Abirami Sivapiragasam
Contact
sivapira@musc.edu
843-792-9300
Abi Siva, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Paclitaxel · Pembrolizumab

Start the discussion